AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F17%3A00077857" target="_blank" >RIV/00209805:_____/17:00077857 - isvavai.cz</a>
Result on the web
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0014-4800(16)30276-3" target="_blank" >https://linkinghub.elsevier.com/retrieve/pii/S0014-4800(16)30276-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.yexmp.2017.02.016" target="_blank" >10.1016/j.yexmp.2017.02.016</a>
Alternative languages
Result language
angličtina
Original language name
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients
Original language description
Expression of the AGR2 oncogenewas shown to be associated with estrogen receptor positive tumors. This gene contributes to enhanced cellular proliferation, drug resistance, metastasis development and may also serve as a predictor of poor prognosis. However, our analysis of AGR2 expression in a subset of estrogen-receptor negative tumors revealed that AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. Moreover, in a subset of estrogen- and progesterone-receptor negative and simultaneously HER2-positive cases, increased AGR2 expression significantly correlated with worse patient prognosis. Subsequent analysis of independent data sets either collected in our institute or obtained from Oncomine cancer microarray database confirmed all these findings.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Experimental and molecular pathology
ISSN
0014-4800
e-ISSN
—
Volume of the periodical
102
Issue of the periodical within the volume
2
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
4
Pages from-to
"280–283"
UT code for WoS article
000403040200017
EID of the result in the Scopus database
2-s2.0-85014107239